A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I
| Autor: | Deirdre R. Pachman, Lauren E. Ta, Kathryn J. Ruddy, Nathan P. Staff, Andreas S. Beutler, Patricia J. Zekan, Nguyet A. Le-Lindqwister, Travis J. Dockter, William M. Sikov, Charles L. Loprinzi, Briant Fruth, Todor Dentchev, Jacqueline M. Lafky |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Paclitaxel
medicine.medical_treatment Pain medicine Minocycline Pilot Projects Placebo 03 medical and health sciences Animal data 0302 clinical medicine Breast cancer Double-Blind Method medicine Humans Chemotherapy business.industry Peripheral Nervous System Diseases Middle Aged medicine.disease Anti-Bacterial Agents Peripheral neuropathy Oncology Chemotherapy-induced peripheral neuropathy 030220 oncology & carcinogenesis Anesthesia Female business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. 25(11) |
| ISSN: | 1433-7339 |
| Popis: | Paclitaxel is associated with both an acute pain syndrome (P-APS) and chronic chemotherapy-induced peripheral neuropathy (CIPN). Given that extensive animal data suggest that minocycline may prevent chemotherapy-induced neurotoxicity, the purpose of this pilot study was to investigate the efficacy of minocycline for the prevention of CIPN and the P-APS. Patients with breast cancer were enrolled prior to initiating neoadjuvant or adjuvant weekly paclitaxel for 12 weeks and were randomized to receive minocycline 200 mg on day 1 followed by 100 mg twice daily or a matching placebo. Patients completed (1) an acute pain syndrome questionnaire daily during chemotherapy to measure P-APS and (2) the EORTC QLQ-CIPN20 questionnaire at baseline, prior to each dose of paclitaxel, and monthly for 6 months post treatment, to measure CIPN. Forty-seven patients were randomized. There were no remarkable differences noted between the minocycline and placebo groups for the overall sensory neuropathy score of the EORTC QLQ-CIPN20 or its individual components, which evaluate tingling, numbness and shooting/burning pain in hands and feet. However, patients taking minocycline had a significant reduction in the daily average pain score attributed to P-APS (p = 0.02). Not only were no increased toxicities reported with minocycline, but there was a significant reduction in fatigue (p = 0.02). Results of this pilot study do not support the use of minocycline to prevent CIPN, but suggest that it may reduce P-APS and decrease fatigue; further study of the impact of this agent on those endpoints may be warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink